CTIM-76's 29% ORR in chemo-resistant ovarian cancer is the only human proof on the table — whether dosing optimization converts that signal into a registrational path decides the thesis

Context Therapeutics is a clinical-stage company developing a cell therapy for platinum-resistant ovarian cancer that is not yet approved.

Context Therapeutics posted a 29% confirmed ORR and 57% disease control rate for CTIM-76, a T cell engager in platinum-resistant ovarian cancer, with only Grade 1 CRS in a notoriously treatment-refractory disease. The thesis resolves on whether the Q3W dosing schedule preserves efficacy while enabling durable T cell recovery sufficient for FDA to accept a streamlined registrational path. The primary risk is that single-arm Phase 1 data may not satisfy regulators without a randomized comparator, and runway only extends to mid-2027, tightly bracketing the dose-optimization readouts.